HUTCHMED (NASDAQ:HCM) Stock Passes Above 50 Day Moving Average – Here’s Why

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $14.40 and traded as high as $14.87. HUTCHMED shares last traded at $14.76, with a volume of 5,329 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HCM shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $20.88.

HUTCHMED Price Performance

The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The firm has a fifty day simple moving average of $14.40 and a 200-day simple moving average of $15.18.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors have recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in HUTCHMED by 131.5% during the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after buying an additional 2,916 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after buying an additional 698 shares in the last quarter. Bank of America Corp DE boosted its position in shares of HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after acquiring an additional 3,035 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of HUTCHMED by 34.2% in the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after acquiring an additional 5,538 shares during the period. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.